Compound class:
Synthetic organic
Comment: JEDI-852 is the hit molecule from a series of antibacterial compounds that target UDP-2,3-diacylglucosamine hydrolase (LpxH), an enzyme in the lipopolysaccharide synthesis pathway [1]. LpxH is an essential enzyme, conserved in the majority of Gram-negative bacteria but absent in human.
|
|
References |
1. Huseby DL, Cao S, Zamaratski E, Sooriyaarachchi S, Ahmad S, Bergfors T, Krasnova L, Pelss J, Ikaunieks M, Loza E et al.. (2024)
Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria. Proc Natl Acad Sci U S A, 121 (15): e2317274121. [PMID:38579010] |